Clinical features of lung adenocarcinomas with epidermal growth factor receptor mutations and miliary disseminated carcinomatosis

Publisher： John Wiley & Sons Inc

E-ISSN： 1759-7714|6|5|629-635

ISSN： 1759-7706

Source： Thoracic Cancer, Vol.6, Iss.5, 2015-09, pp. : 629-635

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy of bronchoscopic biopsy for the detection of epidermal growth factor receptor mutations and anaplastic lymphoma kinase gene rearrangement in lung adenocarcinoma

By  

Thoracic Cancer, Vol. 6, Iss. 6, 2015-11 ,pp. : 709-714

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pitfalls in diagnosis with the use of circulating tumor‐derived epidermal growth factor receptor mutations in lung cancer harboring pretreatment T790M

By  

Thoracic Cancer, Vol. 9, Iss. 1, 2018-01 ,pp. : 171-174

John Wiley & Sons Inc

Access to resources Recommend Favorite

Subsequent treatment of epidermal growth factor receptor‐tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinoma

By  

Thoracic Cancer, Vol. 6, Iss. 6, 2015-11 ,pp. : 678-686

John Wiley & Sons Inc

Access to resources Recommend Favorite

Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lung

By  

Thoracic Cancer, Vol. 6, Iss. 3, 2015-05 ,pp. : 319-326

John Wiley & Sons Inc

Access to resources Recommend Favorite

Histological transformation from non‐small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor‐tyrosine kinase inhibitor

By  

Thoracic Cancer, Vol. 6, Iss. 6, 2015-11 ,pp. : 800-804

John Wiley & Sons Inc

Access to resources Recommend Favorite